中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial

文献类型：期刊论文

作者Liu, Jihong19,20; Yin, Rutie17,18; Wu, Lingying16; Zhu, Jianqing15; Lou, Ge14; Wu, Xiaohua13; Zhou, Qi12; Gao, Yunong11; Kong, Beihua10; Lu, Xin1
刊名ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
出版日期2022-03-31
关键词BRCA mutation China olaparib ovarian cancer PARP inhibitor
ISSN号1743-7555
DOI10.1111/ajco.13753
通讯作者Liu, Jihong(liujh@sysucc.org.cn)
英文摘要Aim The phase III SOLO2 global study demonstrated the efficacy and safety of maintenance olaparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, in platinum-sensitive relapsed ovarian cancer patients with a BRCA mutation. This separate China cohort of SOLO2 investigated the efficacy and safety of maintenance olaparib in Chinese patients. Methods Patients received olaparib (300 mg twice daily, oral, tablets) or matched placebo. Primary endpoint was investigator-assessed progression-free survival (Response Evaluation Criteria in Solid Tumors version 1.1). Safety and tolerability were also assessed. Results Thirty-two patients were treated. Olaparib treatment led to an improvement in progression-free survival compared with placebo (hazard ratio = 0.44, 95% confidence interval: 0.17-1.19; median = 13.8 vs. 5.5 months). Results of secondary efficacy endpoints of time to first subsequent treatment/death and time to treatment discontinuation/death were consistent with progression-free survival results. Time to second progression/death and time to second subsequent treatment/death data were immature at data cutoff. The most common adverse events in the olaparib arm were nausea (81.8%), anemia (45.5%), and decreased appetite (36.4%). Grade >= 3 adverse events were experienced by 36.4% of olaparib and 10.0% of placebo patients. No adverse events led to discontinuation of treatment. There were six deaths (olaparib, five; placebo, one); one death in the olaparib arm was due to an unknown cause, all others were related to disease progression. Conclusions Efficacy and safety findings in the China SOLO2 cohort support the use of olaparib (300 mg twice daily) as maintenance treatment for Chinese patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation.
WOS关键词THERAPY
资助项目AstraZeneca ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA
WOS研究方向Oncology
语种英语
WOS记录号WOS:000776130800001
出版者WILEY
资助机构AstraZeneca ; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,Kenilworth, NJ, USA
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/128293]  
专题中国科学院合肥物质科学研究院
通讯作者Liu, Jihong
作者单位1.Fudan Univ, Obstet & Gynecol Hosp, Shanghai, Peoples R China
2.Celgene, San Diego, CA USA
3.AstraZeneca, Shanghai, Peoples R China
4.First Hosp Jilin Univ, Oncol Ctr, Changchun, Peoples R China
5.Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou, Peoples R China
6.Xi An Jiao Tong Univ, 1 Affiliated Hosp, Med Sch, Xian, Peoples R China
7.Jilin Canc Hosp, Changchun, Peoples R China
8.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
9.Hunan Canc Hosp, Changsha, Peoples R China
10.Shandong Univ, Qilu Hosp, Jinan, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Jihong,Yin, Rutie,Wu, Lingying,et al. Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,2022.
APA Liu, Jihong.,Yin, Rutie.,Wu, Lingying.,Zhu, Jianqing.,Lou, Ge.,...&Hsu, Kate.(2022).Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
MLA Liu, Jihong,et al."Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。